Cyril Allouche Net Worth & Insider Trades
Cyril Allouche - Principal Accounting Officer, Revance Therapeutics, Inc
What is Cyril Allouche's Net Worth?
The current estimated net worth of Revance Therapeutics, Inc's Principal Accounting Officer, Cyril Allouche, is estimated to be about $204.03K . Cyril Allouche owns about 6,400 units of Revance Therapeutics, Inc common stock. In the last year at Revance Therapeutics, Inc, Cyril Allouche has sold an estimated value of $108.64K worth.
What is Cyril Allouche's Past Insider Trading?
Cyril Allouche's largest purchase order was 2,188 units , worth over $29.21K on November 9, 2018. Cyril Allouche's largest sale order was 2,188 units , worth over $51.9K on November 9, 2018. In total, Cyril Allouche has made about 11 transactions over a year of their time at Revance Therapeutics, Inc. Cyril Allouche usually trades in January, with the busiest year in 2018. The most recent transaction was a sale order of 750 units , worth over $11.6K on March 19, 2019.
Cyril Allouche
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What is Cyril Allouche's' Mailing Address?
- Mailing address is 7555 Gateway Blvd. Newark CA 94560 CA
Revance Therapeutics, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|---|
| Mark J. Foley | 2020 | $650,000 | - | $7,794,350 | - | $328,331 | $8,255 | $8,780,936 |
| Mark J. Foley | 2019 | $189,764 | $150,000 | $11,728,370 | $5,112,573 | - | $9,723 | $17,190,430 |
| Tobin C. Schilke | 2020 | $421,375 | - | $1,131,345 | $1,273,662 | $143,186 | $11,531 | $2,981,099 |
| Tobin C. Schilke | 2019 | $407,126 | $25,000 | $86,150 | $299,781 | $178,123 | $11,078 | $1,007,258 |
| Tobin C. Schilke | 2018 | $64,644 | $25,000 | $449,280 | $1,434,350 | - | $233 | $1,973,507 |
| Abhay Joshi, Ph.D. | 2020 | $514,608 | - | $1,405,850 | $1,913,759 | $213,726 | $11,731 | $4,059,674 |
| Abhay Joshi, Ph.D. | 2019 | $485,479 | - | $271,373 | $939,314 | $204,211 | $9,520 | $1,909,897 |
| Abhay Joshi, Ph.D. | 2018 | $469,062 | - | $342,513 | $1,192,465 | $232,186 | $9,210 | $2,245,436 |
| Dustin Sjuts | 2020 | $415,000 | - | $1,294,250 | $1,306,320 | $141,020 | $66,242 | $3,222,832 |
| Dustin Sjuts | 2019 | $378,333 | $50,000 | $43,075 | $99,927 | $183,902 | $45,786 | $801,023 |
| Dwight Moxie | 2020 | $370,104 | $125,000 | $1,309,383 | $2,579,240 | $125,426 | $10,356 | $4,519,508 |
| No matching records found | ||||||||
Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000089/rvncfy20proxystatementdef1.htm
What are Revance Therapeutics, Inc's Past Insider Trades?
Revance Therapeutics, Inc's most recent insider trade came on September 16, 2022 by Dwight Moxie who sold 11,000 units worth $297.8K . In the last 8 years, insiders at Revance Therapeutics, Inc have sold an estimated value of $30.1M and bought an estimated value of $8.63M worth of shares. Insider trading is most common in May, with the busiest year in 2021. The most active traders at the company are Daniel Browne, CEO and President, Curtis Ruegg, EVP, and Lauren Silvernail, CFO & CBO .
Revance Therapeutics, Inc. Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||